{
    "nctId": "NCT00651976",
    "briefTitle": "Letrozole in Treating Postmenopausal Women With Stage I, II or III Breast Cancer That Can Be Removed by Surgery",
    "officialTitle": "Pre-Surgical Trial of Letrozole in Post-Menopausal Patients With Operable Hormone-Sensitive Breast Cancer (Spore)",
    "overallStatus": "TERMINATED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "EARLY_PHASE1",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 213,
    "primaryOutcomeMeasure": "Ki67 index measured in hormone receptor-positive breast cancers compared to those that are hormone receptor-negative",
    "eligibilityCriteria": "DISEASE CHARACTERISTICS:\n\n* Diagnosis of invasive breast cancer\n\n  * Clinical stage I, II, or III disease\n  * Resectable disease\n* Measurable disease, defined as a mass that can be reproducibly measured by physical examination and/or ultrasound and is at least 1 cm in size by ultrasound\n\n  * Patients with measurable residual tumor at the primary site allowed\n* Estrogen receptor-positive tumor by immunohistochemistry (IHC)\n* HER2-negative tumor by Herceptest (0 or +1) OR HER2 not overexpressed by fluorescence in situ hybridization (FISH)\n* Planning to undergo surgical treatment with either segmental resection or total mastectomy with or without lymph node evaluation\n* Must have core biopsies from the time of diagnosis available (may include sections of paraffin-embedded material)\n* Prior contralateral breast cancer allowed provided there is no evidence of recurrence of the initial primary breast cancer\n* Patients with locally advanced disease who are candidates for preoperative chemotherapy at the time of initial evaluation are not eligible\n\n  * Locally advanced disease is defined by any of the following:\n\n    * Primary tumor \u2265 5 cm (T3)\n    * Tumor of any size with direct extension to the chest wall or skin (T4a-c)\n    * Inflammatory breast cancer (T4d)\n    * Fixed axillary lymph node metastases (N2)\n    * Metastasis to ipsilateral internal mammary node (N3)\n* No locally recurrent disease\n* No evidence of distant metastatic disease (i.e., lung, liver, bone, or brain metastases)\n\nPATIENT CHARACTERISTICS:\n\n* ECOG performance status 0-1\n* Postmenopausal, as defined by any of the following:\n\n  * 55 years of age and over\n  * Under 55 years of age and meets 1 of the following criteria:\n\n    * Amenorrheic for at least 12 months\n    * Follicle-stimulating hormone (FSH) \u2265 40 IU/L and estradiol levels \u2264 20 IU/L\n  * Has undergone prior bilateral oophorectomy or radiation castration AND has been amenorrheic for at least 6 months\n* Bilirubin \u2264 1.5 times upper limit of normal (ULN)\n* SGOT and SGPT \u2264 1.5 times ULN\n* Creatinine \u2264 1.5 t times ULN\n* Able to swallow and retain oral medication\n* No serious medical illness that, in the judgment of the treating physician, places the patient at high risk for operative mortality\n* No malabsorption syndrome, ulcerative colitis, or other disease significantly affecting gastrointestinal function\n* No other malignancy within the past 5 years except for completely resected nonmelanoma skin cancer or successfully treated in situ carcinoma\n* No dementia, altered mental status, or any psychiatric condition that would preclude the understanding or rendering of informed consent\n* No severe uncontrolled malabsorption condition or disease (i.e., grade II/III diarrhea, severe malnutrition, or short gut syndrome)\n\nPRIOR CONCURRENT THERAPY:\n\n* See Disease Characteristics\n* At least 21 days since prior tamoxifen or raloxifene as a preventive agent\n* At least 7 days since prior hormone replacement therapy (e.g., conjugated estrogens \\[Premarin\\])\n* No prior resection of the stomach or small bowel\n* More than 30 days or 5 half-lives, whichever is longer, since prior investigational drugs\n* No prior chemotherapy for this primary breast cancer\n* No other concurrent investigational agents\n* No other concurrent anticancer therapy (e.g., chemotherapy, radiotherapy, immunotherapy, hormonal therapy, or any other biologic therapy)",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}